Total Payments
$247,706
2024 Payments
$2,344
Companies
25
Transactions
337
Medicare Patients
1,650
Medicare Billing
$198,932
Payment Breakdown by Category
Other$133,135 (53.7%)
Consulting$59,158 (23.9%)
Travel$32,791 (13.2%)
Food & Beverage$16,235 (6.6%)
Research$6,382 (2.6%)
Education$6.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $133,135 | 40 | 53.7% |
| Consulting Fee | $59,158 | 23 | 23.9% |
| Travel and Lodging | $32,791 | 74 | 13.2% |
| Food and Beverage | $16,235 | 192 | 6.6% |
| Unspecified | $6,382 | 5 | 2.6% |
| Education | $6.00 | 3 | 0.0% |
Payments by Type
General
$241,325
332 transactions
Research
$6,382
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $106,268 | 130 | $0 (2023) |
| United Therapeutics Corporation | $41,788 | 59 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $41,429 | 47 | $0 (2022) |
| Genentech USA, Inc. | $28,472 | 25 | $0 (2019) |
| Actelion Pharmaceuticals, Ltd | $10,964 | 23 | $0 (2018) |
| Mallinckrodt LLC | $6,382 | 5 | $0 (2017) |
| KAMADA LTD. | $4,474 | 17 | $0 (2024) |
| PFIZER INC. | $2,964 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,750 | 2 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $1,680 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,344 | 13 | GlaxoSmithKline, LLC. ($1,750) |
| 2023 | $7,625 | 26 | KAMADA LTD. ($4,253) |
| 2022 | $6,756 | 15 | Bayer HealthCare Pharmaceuticals Inc. ($6,000) |
| 2021 | $5,608 | 7 | United Therapeutics Corporation ($2,438) |
| 2020 | $5,901 | 12 | United Therapeutics Corporation ($4,155) |
| 2019 | $31,692 | 33 | United Therapeutics Corporation ($16,604) |
| 2018 | $34,149 | 66 | Actelion Pharmaceuticals US, Inc. ($20,147) |
| 2017 | $153,632 | 165 | Actelion Pharmaceuticals US, Inc. ($85,940) |
All Payment Transactions
337 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Airway Clearance Device | ||||||
| 10/28/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $89.36 | General |
| Category: Infectious Disease | ||||||
| 08/20/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $150.17 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 08/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological), AREXVY | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/18/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $81.42 | General |
| Category: Infectious Disease | ||||||
| 05/09/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Pulmonology | ||||||
| 05/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/29/2024 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $39.85 | General |
| Category: VTE | ||||||
| 01/23/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $18.62 | General |
| Category: Infectious Disease | ||||||
| 01/22/2024 | Paragonix Technologies, Inc. | SherpaPak (Device), LiverGuard, LungGuard | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: Cardiology | ||||||
| 01/21/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $17.73 | General |
| Category: Infectious Disease | ||||||
| 01/20/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $13.88 | General |
| Category: Infectious Disease | ||||||
| 01/04/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 12/12/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $116.15 | General |
| Category: PAH | ||||||
| 10/14/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $1,247.99 | General |
| Category: Immunology | ||||||
| 10/14/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $1,247.99 | General |
| Category: Immunology | ||||||
| 10/14/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $5.88 | General |
| Category: Immunology | ||||||
| 10/13/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $21.05 | General |
| Category: Immunology | ||||||
| 10/13/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $14.12 | General |
| Category: Immunology | ||||||
| 09/29/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Cardiology | ||||||
| 09/01/2023 | KAMADA LTD. | CYTOGAM (Drug) | Travel and Lodging | Cash or cash equivalent | $958.33 | General |
| Category: Immunology | ||||||
| 08/10/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $138.45 | General |
| Category: PAH | ||||||
| 08/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug), OFEV | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: RESPIRATORY | ||||||
| 07/21/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $139.09 | General |
| Category: Cardiology | ||||||
| 06/02/2023 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $363.81 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 492 | 844 | $271,915 | $54,486 |
| 2022 | 14 | 506 | 825 | $311,821 | $61,564 |
| 2021 | 10 | 365 | 627 | $179,417 | $42,541 |
| 2020 | 10 | 287 | 506 | $206,821 | $40,340 |
Total Patients
1,650
Total Services
2,802
Medicare Billing
$198,932
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 75 | 317 | $106,512 | $29,506 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 51 | $23,664 | $5,540 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 65 | $22,360 | $4,910 | 22.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 24 | $15,696 | $3,202 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $13,280 | $2,860 | 21.5% |
| 31628 | Biopsy of lobe of lung using an endoscope, 1 lobe | Facility | 2023 | 16 | 18 | $26,874 | $2,446 | 9.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 24 | 27 | $9,207 | $2,372 | 25.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 79 | 85 | $11,560 | $1,426 | 12.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 114 | 174 | $5,568 | $1,096 | 19.7% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 21 | 25 | $29,100 | $760.26 | 2.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 25 | 38 | $8,094 | $367.46 | 4.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 64 | 248 | $83,328 | $20,042 | 24.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 20 | 81 | $75,573 | $13,816 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 113 | 150 | $51,600 | $12,256 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $11,952 | $2,581 | 21.6% |
| 31628 | Biopsy of lobe of lung using an endoscope, 1 lobe | Facility | 2022 | 14 | 15 | $20,355 | $2,097 | 10.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 13 | $8,502 | $2,028 | 23.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 20 | 25 | $3,000 | $1,456 | 48.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $5,104 | $1,318 | 25.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 68 | 72 | $7,632 | $1,264 | 16.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 15 | $5,115 | $1,249 | 24.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 14 | $2,240 | $1,167 | 52.1% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 24 | 26 | $27,508 | $1,150 | 4.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 78 | 96 | $2,784 | $616.60 | 22.1% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 13 | 15 | $1,590 | $267.72 | 16.8% |
About Dr. Fernando Torres, M.D
Dr. Fernando Torres, M.D is a Pulmonary Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205856366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fernando Torres, M.D has received a total of $247,706 in payments from pharmaceutical and medical device companies, with $2,344 received in 2024. These payments were reported across 337 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($133,135).
As a Medicare-enrolled provider, Torres has provided services to 1,650 Medicare beneficiaries, totaling 2,802 services with total Medicare billing of $198,932. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Dallas, TX
- Active Since 07/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1205856366
Products in Payments
- Adempas (Drug) $41,429
- Esbriet (Biological) $28,339
- UPTRAVI (Drug) $27,861
- OPSUMIT MACITENTAN (Drug) $27,689
- NONE (Drug) $15,892
- ORENITRAM (Drug) $9,234
- CYTOGAM (Drug) $4,474
- TYVASO (Drug) $3,255
- VIAGRA (Drug) $2,964
- NUZYRA (Drug) $1,680
- GIAPREZA (Drug) $464.31
- TREPROSTINIL (Drug) $310.70
- Xolair (Biological) $133.13
- NUCALA (Biological) $125.00
- SherpaPak (Device) $122.31
- SIMPONI ARIA (Biological) $121.30
- REMODULIN (Drug) $107.84
- Actemra (Biological) $107.31
- REMICADE (Biological) $65.18
- OFEV (Drug) $47.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Dallas
Dr. Mark Millard, M.d, M.D
Pulmonary Disease — Payments: $381,124
Pulmonary Disease $381,124
Dr. Raksha Jain, Md, MD
Pulmonary Disease — Payments: $189,093
Pulmonary Disease $189,093
Dr. Kelly Chin, M.d, M.D
Pulmonary Disease — Payments: $103,886
Pulmonary Disease $103,886
Dr. Gary Weinstein, M.d, M.D
Pulmonary Disease — Payments: $102,068
Pulmonary Disease $102,068
Anthony Ortegon, Md, MD
Pulmonary Disease — Payments: $95,730
Pulmonary Disease $95,730
Dr. Abhishek Kumar, M.d, M.D
Pulmonary Disease — Payments: $47,973
Pulmonary Disease $47,973